On Rare Disease Day 2026, Certara experts share how cross-functional innovation, regulatory strategies for rare…
CertaraFebruary 26, 2026
From Documentation to Design: Building a Scalable Metadata Strategy for Clinical Research
Learn how clinical teams are treating metadata as infrastructure to improve reuse, auditability, and standards…
CertaraFebruary 26, 2026
Metatdata as Infrastructure: Designing for Reuse, Insight, and Auditability
Watch this on-demand webinar to learn how leading clinical teams design scalable metadata strategies that…
CertaraFebruary 26, 2026
Start right, finish strong: Antibody-drug conjugate (ADC) studies for success
Learn how to build regulatory-ready first-in-human (FIH) dose strategies for antibody-drug conjugates (ADCs). Discover how…
CertaraFebruary 23, 2026
FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug Development
Learn what the ICH M15 guideline means for Model-Informed Drug Development, regulatory credibility, harmonization, and…
CertaraFebruary 18, 2026
Pediatric Drug Development: From “Wild West” to Model-Informed Confidence
Model-informed drug development and precision dosing are transforming pediatric programs, from regulatory planning to Bayesian…
CertaraFebruary 11, 2026
Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants
This study, published in Clinical Pharmacology & Therapeutics (CPT), shows how population pharmacokinetic modeling supports…
CertaraFebruary 2, 2026
P21 Enterprise Expands Regulatory Validation Capabilities with Support for the Tobacco Implementation Guide v1.0
Pinnacle 21 supports TIG v1.0, the CDISC Tobacco Implementation Guide for FDA CTP, enabling automated…
CertaraJanuary 30, 2026
How Model-Informed Drug Development (MIDD) Strengthens Drug Asset Valuation and Answers the Questions Investors Care About Most
Learn how Model-Informed Drug Development strengthens drug asset valuation by reducing uncertainty, predicting clinical performance,…
CertaraJanuary 26, 2026
Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients
This article explores how model-based meta-analysis (MBMA) performs when combining aggregate data and individual patient…
CertaraJanuary 22, 2026
